


PHARMACEUTICAL 2022



## FIBROGEN INC Rank 266 of 475







PHARMACEUTICAL 2022



FIBROGEN INC Rank 266 of 475

The relative strengths and weaknesses of FIBROGEN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of FIBROGEN INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 85% points. The greatest weakness of FIBROGEN INC is the variable Assets, Current, reducing the Economic Capital Ratio by 92% points.

The company's Economic Capital Ratio, given in the ranking table, is -140%, being 136% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	474,059
Cost of Goods Sold	12,871
Intangible Assets	0
Liabilities, Current	225,497
Liabilities, Non-Current	301,595
Other Assets	271,485
Other Compr. Net Income	336
Other Expenses	347
Other Liabilities	17,616
Other Net Income	-1,146
Property and Equipment	28,277
Research and Development	387,043
Revenues	235,309
Selling, General and Administrative Expense	123,925

Output Variable	Value in 1000 USD
Assets	773,821
Liabilities	544,708
Expenses	524,186
Stockholders Equity	229,113
Net Income	-290,023
Comprehensive Net Income	-289,855
Economic Capital Ratio	-140%

